Antibe Therapeutics (CVE:ATE) Stock Price Up 14.3%

Antibe Therapeutics Inc (CVE:ATE) shares rose 14.3% during trading on Thursday . The company traded as high as C$0.34 and last traded at C$0.32, approximately 3,873,932 shares changed hands during trading. An increase of 680% from the average daily volume of 496,356 shares. The stock had previously closed at C$0.28.

The company’s 50-day moving average price is C$0.32. The company has a market capitalization of $68.15 million and a price-to-earnings ratio of -5.75. The company has a debt-to-equity ratio of 27.85, a quick ratio of 2.51 and a current ratio of 3.63.

About Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

Read More: Beige Book

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.